# A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

> **NCT02532855** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 614 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Dapagliflozin
- **DRUG:** Metformin
- **DRUG:** Matching placebo to sitagliptin
- **DRUG:** Matching placebo to dapagliflozin
- **DRUG:** Sulfonylurea

## Key facts

- **NCT ID:** NCT02532855
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-20
- **Primary completion:** 2017-10-10
- **Final completion:** 2017-10-10
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532855, "A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02532855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*